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Abstract. 
 
The extracellular matrix exerts a stringent 
control on the proliferation of normal cells, suggesting 
the existence of a mitogenic signaling pathway acti-
vated by integrins, but not signiﬁcantly by growth factor 
receptors. Herein, we provide evidence that integrins 
cause a signiﬁcant and protracted activation of Jun 
NH
 
2
 
-terminal kinase (JNK), while several growth fac-
tors cause more modest or no activation of this enzyme. 
Integrin-mediated stimulation of JNK required the as-
sociation of focal adhesion kinase (FAK) with a Src ki-
nase and p130
 
CAS
 
, the phosphorylation of p130
 
CAS
 
, and 
subsequently, the recruitment of Crk. Ras and PI-3K 
were not required. FAK–JNK signaling was necessary 
for proper progression through the G1 phase of the cell 
cycle. These ﬁndings establish a role for FAK in both 
the activation of JNK and the control of the cell cycle, 
and identify a physiological stimulus for JNK signaling 
that is consistent with the role of Jun in both prolifera-
tion and transformation.
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N
 
ORMAL
 
 cells require adhesion to extracellular ma-
trix components to proliferate in vitro, suggesting
that integrins activate signaling pathways that are
necessary for cell cycle progression (reviewed in Giancotti,
1997). In principle, integrins could cooperate with growth
factor receptors to produce a synergistic stimulation of
one or more mitogenic signaling pathways. Indeed, the re-
sults of several studies support this model (reviewed in
Ruoslahti and Reed, 1994; Clark and Brugge, 1995; Par-
sons, 1996; Clark and Hynes, 1997; Schwartz, 1997; Ya-
mada and Geiger, 1997; Howe et al., 1998; Schlaepfer and
Hunter, 1998). However, such a mechanism does not
readily explain the strict adhesion requirement for growth
displayed by normal cells. In addition, or instead, integrins
could activate a signaling pathway that is not significantly
activated by growth factors, but is necessary for cell prolif-
eration. The identification of such a pathway would pro-
vide a more complete understanding of the anchorage-
dependent growth than is currently available.
Integrins activate common, as well as subgroup-specific,
signaling pathways. A subset of integrins, which includes
 
a
 
1
 
b
 
1, 
 
a
 
5
 
b
 
1, 
 
a
 
v
 
b
 
3, and 
 
a
 
6
 
b
 
4, is coupled to the Ras-extra-
cellular signal-regulated kinase (ERK)
 
1
 
 signaling pathway
by the adaptor protein Shc (Mainiero et al., 1995; Wary et al.,
1996). Shc binds directly to the uniquely large cytoplasmic
domain of 
 
b
 
4 when this integrin undergoes tyrosine phos-
phorylation (Mainiero et al., 1995; 1997). In contrast, the
recruitment of Shc by 
 
b
 
1 and 
 
a
 
v integrins is indirect, re-
quiring the interaction of the integrin 
 
a
 
 subunit with the
membrane adaptor caveolin-1 and associated tyrosine ki-
nase, Fyn (Wary et al., 1998). Biochemical and genetic evi-
dence suggest that integrins recruit Shc independently of
focal adhesion kinase (FAK), and that this event is neces-
sary and sufficient to activate the Ras-ERK pathway. In
primary cells, inhibition of integrin-mediated Shc signaling
results in cell cycle arrest, despite the presence of growth
factors, suggesting that a combined stimulation of Ras by
Shc-linked integrins and growth factor receptors is re-
quired for progression through the G1 phase of the cell cy-
cle (Wary et al., 1996, 1998).
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Certain integrins appear to associate preferentially with
specific growth factor receptors and contribute to their ac-
tivation (Miyamoto et al., 1996; Schneller et al., 1997;
Moro et al., 1998; Soldi et al., 1999). For example, 
 
a
 
v
 
b
 
3
combines with the platelet-derived growth factor (PDGF)
receptor. Hence, fibroblasts show enhanced proliferation
in response to PDGF when attaching to the 
 
a
 
v
 
b
 
3 ligand
vitronectin than they do on the 
 
b
 
1 integrin ligand collagen
(Schneller et al., 1997). The selective association of inte-
grins with growth factor receptors represents a second po-
tential mechanism of integrin-specific growth control.
Whereas the aforementioned pathways are activated
only by certain integrins, the tyrosine kinase FAK is acti-
vated by most integrins (Parsons, 1996). Activated FAK
undergoes autophosphorylation at Tyr 397 and thereby
binds to the SH2 domain of the Src-family kinase Src or
Fyn (Schaller et al., 1994; Schlaepfer et al., 1994). The Src-
family kinase then phosphorylates a number of FAK-asso-
ciated proteins, including p130
 
CAS
 
 and paxillin, which con-
tain multiple docking sites for the adaptor proteins Crk
and Nck (Schaller and Parsons, 1995; Richardson and Par-
sons, 1996; Vuori et al., 1996; Schlaepfer et al., 1997). In
addition, Src phosphorylates FAK at a tyrosine residue
able to recruit Grb2 (Schlaepfer et al., 1994). It is possible
that FAK contributes to the activation of the Ras-ERK
cascade by these (Schlaepfer et al., 1997) and potentially
other mechanisms (Chen et al., 1996; King et al., 1997; Lin
et al., 1997; Renshaw et al., 1997). Although previous stud-
ies have provided direct evidence for a role of FAK in cell
migration (Ilic et al., 1995; Fincham and Frame, 1998; Cary
et al., 1998; Klemke et al., 1998) and protection from apop-
totic cell death (Frisch et al., 1996b; Ilic et al., 1998), it is
unclear whether FAK also regulates cell proliferation, and
if so, by what mechanism.
Integrin-mediated adhesion activates not only ERK, but
also Jun NH
 
2
 
-terminal kinase (JNK; Miyamoto et al., 1995;
Mainiero et al., 1997; MacKenna et al., 1998). JNK is the
final element of a mitogen-activated protein kinase (MAPK)
cascade known to be activated by stress stimuli, such as
UV radiation, hyperosmolar conditions, and inflammatory
cytokines (Ip and Davis, 1998). Upon activation, JNK en-
ters the nucleus, and phosphorylates and activates the
transcription factors c-Jun and activating transcription fac-
tor 2 (ATF2), thereby regulating AP-1–dependent tran-
scription (Karin et al., 1997). Because there is evidence
that c-Jun is required for cell proliferation (Riabowol et
al., 1992; Johnson et al., 1993), we sought to examine the
mechanism by which integrins activate JNK and test the
hypothesis that activation of this signaling pathway con-
tributes to the control of cell cycle progression.
Our results indicate that integrins cause a significant and
protracted activation of JNK, while growth factors appear
to be unable to do so. By using various dominant-negative
signaling molecules, we provide evidence that the activa-
tion of JNK by integrins is mediated by FAK and is neces-
sary for cell cycle progression.
 
Materials and Methods
 
Antibodies and Extracellular Matrix Proteins
 
The mAb M2 to FLAG tag was purchased from Eastman-Kodak and the
anti-CD2 mAb RPA-2.10 from PharMingen. The anti-H–Ras mAb
R02120 (clone 18) and anti-p130
 
CAS
 
 mAb P27820 (clone 21) were from
Transduction Laboratories. The origin and specificity of the affinity-puri-
fied rabbit antibodies to ERK2, phospho-ERK, Src, and GST and of the
anti–5-bromodeoxyuridine (anti-BrdU) mAb were described previously
(Wary et al., 1996; 1998). The mAb 3C2 reacting with the gag portion of
v-Crk was also described previously (Potts et al., 1987). Human fibronec-
tin was from GIBCO BRL and poly-
 
L
 
-lysine from Sigma Chemical Co.
 
Cell Lines, Constructs, and Transfections
 
293 human embryonic kidney cells were cultured in DME 10% FCS on
gelatin-coated plates. NIH-3T3 mouse fibroblasts were cultured in DME
10% calf serum (CS). Fibroblasts from Src
 
2
 
/
 
2
 
 and Fyn
 
2
 
/
 
2
 
 embryos were
obtained from Philippe Soriano (Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA) and cultured in DME 10% CS. Human umbilical vein
endothelial cells (HUVECs) were purchased from Clonetics and cultured
on gelatin-coated dishes in human endothelial serum-free medium (SFM;
GIBCO BRL) supplemented with 20% FCS (GIBCO BRL), 10 ng/ml
EGF, 20 ng/ml bFGF, and 1 
 
m
 
g/ml heparin (all from Intergen).
The reporter plasmid pcoll TRE-tk-Luc, in which the expression of lu-
ciferase is driven by a single copy of the collagen gene 12-O-tetradeca-
noylphorbol-13-aretate (TPA)-responsive element (TRE) linked to the
Hepes simplex virus thymidine kinase minimal promoter, was described
previously (Galien et al., 1994). Vectors encoding the FLAG-tagged ver-
sion of JNK 1, glutatione S-transferase (GST)-Jun, dominant-negative
Ras (N17), and HA-tagged 
 
b
 
-galactosidase were described previously
(Mainiero et al., 1997). The CMV promotor-based pCDM8 vectors encod-
ing CD2-FAK (wild-type), CD2-FAK K454R (kinase dead), and CD2-
FAK Y397F were described previously (Chan et al., 1994). A kinase dead
version of chicken c-Src was obtained from Sara Courtneidge (EMBL,
Heidelberg, Germany) and subcloned in the cytomegalovirus (CMV) pro-
motor-based vector pRK5. The pEBG vectors expressing GST-tagged
MKK4 (wild-type) and MKK4 K129R (kinase dead) from the human
elongation factor 1-
 
a
 
 promoter were described previously (Su et al.,
1997). The Moloney Leukemia Virus (MLV)-LTR based pMEXneo vec-
tors encoding v-Crk (wild-type), v-Crk R273N (SH2 mutant), and v-Crk
D386DRHAD (SH3 insertional mutant) were described previously (Al-
tun-Gultekin et al., 1998). The pEBG vectors encoding GST-tagged rat
p130CAS (short form) and its substrate region deleted form (SD, 
 
D
 
213–
514) were also described (Mayer et al., 1995). The TAM-67 transactiva-
tion domain mutant form of c-Jun (Jun 
 
D
 
3–122) was expressed from
pCMV and previously characterized (Brown et al., 1993). The dominant-
negative version of paxillin used in this study carries three phenylalanine
permutations at tyrosine 31, 118, and 187 and is unable to bind to Crk. The
MLV–LTR-based expression vector p
 
D
 
raf-22w encodes an activated ver-
sion of c-Raf 1 lacking an NH
 
2
 
-terminal segment of 305 amino acids (Stan-
ton et al., 1989). The vector encoding activated Ras, pDCR-Ha-ras
(G12V), was kindly provided by John Westwick (Signal Pharmaceuticals).
NIH-3T3 cells were transiently transfected with Lipofectamine accord-
ing to the manufacturer’s instructions (GIBCO BRL). 293 cells were
plated at 6 
 
3
 
 10
 
6
 
 per 15-cm diam dish for 8 h and then transfected over-
night with various amounts of plasmid by the calcium phosphate method.
All transfections were normalized to the same total amount of DNA with
empty vector. Cells were allowed to recover for 12 h before growth factor
starvation.
 
Biochemical Methods
 
To monitor the activation of JNK and ERK during G1, HUVECs were
synchronized in G0 by a 24 h incubation in human endothelial SFM con-
taining 0.2% FCS. They were then detached with 0.02% EDTA, collected
in SFM containing 0.2% heat-inactivated BSA, washed in the same me-
dium, and kept in suspension at a density of 10
 
6
 
/ml for 15 min at room
temperature to recover. Aliquots consisting of 1.5 
 
3
 
 10
 
7
 
 cells were plated
on 15-cm diam dishes coated with 20 
 
m
 
g/ml fibronectin and postcoated
with 0.2% heat-inactivated BSA in SFM supplemented with ITS
 
1
 
1
(Sigma Chemical Co.), EGF (10 ng/ml), bFGF (20 ng/ml), and heparin (1
 
m
 
g/ml) for the indicated times. Cells from an identical aliquot were pel-
leted and lysed in suspension as a control. Before biochemical analysis,
NIH-3T3 cells were serum starved for 18 h and 293 cells for 24 h in DME
containing 0.2% CS or FCS, respectively. After detachment with 0.02%
EDTA, cells were collected in DME containing 0.2% heat-inactivated
BSA, washed in the same medium, and kept in suspension at a density of
10
 
6
 
/ml for 15 min at room temperature to recover. Aliquots consisting of
1.5 
 
3
 
 10
 
7
 
 cells were plated on 15-cm diam dishes, coated with 20 
 
m
 
g/ml fi-
bronectin and postcoated with 0.2% heat-inactivated BSA for the indi-
cated times. Cells from an identical aliquot were pelleted and lysed in sus- 
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pension as a control. NIH-3T3 cells were treated with growth factors as
indicated.
To analyze the activation of JNK, cells were extracted for 30 min on
ice with 0.5 ml/dish of modified Triton lysis buffer (25 mM Hepes, pH 7.5,
300 mM NaCl, 0.1% Triton X-100, 0.2 mM EDTA, 20 mM 
 
b
 
-glycerophos-
phate, 1.5 mM MgCl
 
2
 
, and 0.5 mM DTT) containing phosphatase and pro-
tease inhibitors. Aliquots containing 0.5 mg of total proteins were brought
to 0.8 ml with modified Triton lysis buffer and diluted to 1.2 ml with HBB
buffer (20 mM Hepes, pH 7.7, 50 mM NaCl, 0.05% Triton X-100, 0.1 mM
EDTA, 20 mM 
 
b
 
-glycerophosphate, 2.5 mM MgCl
 
2
 
, and 10 mM DTT)
supplemented with phosphatase and protease inhibitors. Endogenous
JNK was precipitated with 5 
 
m
 
g of GST-Jun fusion protein coupled to glu-
tathione agarose beads (Hibi et al., 1993). The beads were washed four
times in HBB buffer, twice in kinase buffer (20 mM Hepes pH 7.5, 20 mM
 
b
 
-glycerophosphate, 10 mM MgCl
 
2
 
, and 10 mM DTT), and incubated with
35 
 
m
 
l of kinase buffer containing 10 
 
m
 
Ci of 
 
g
 
[
 
32
 
P]ATP (ICN) and 20 
 
m
 
M
cold ATP. Recombinant FLAG-tagged JNK 1 was immunoprecipitated
with the anti-Flag mAb M2. The beads were washed as above and incu-
bated with 35 
 
m
 
l of kinase buffer containing 5 
 
m
 
g of GST-Jun, 10 
 
m
 
Ci of
 
g
 
[
 
32
 
P]ATP, and 20 
 
m
 
M cold ATP. After 30 min of incubation at 30
 
8
 
C, the
samples were boiled in sample buffer and separated by SDS-PAGE.
Immunoprecipitation and immunoblotting were performed essentially
as described previously (Mainiero et al., 1995). Secondary reagents for im-
munoblotting included peroxidase-conjugated protein A and affinity-puri-
fied rabbit anti–goat IgGs.
To measure transcription from the collagen promotor TRE, NIH-3T3
cells were transiently transfected with the reporter plasmid pcoll TRE-tk-
Luc. After 24 h of growth factor starvation, the cells were detached, kept
in suspension for 30 min, and then solubilized or plated on dishes coated
with 20 
 
m
 
g/ml fibronectin for the indicated times in the absence or pres-
ence of 20 ng/ml PDGF. Luciferase activity in cell lysates was estimated as
described previously (Mainiero et al., 1997).
 
Analysis of Cell Cycle Progression
 
NIH-3T3 cells were transiently transfected with vector encoding 
 
b
 
-galac-
tosidase in combination with various doses of the indicated constructs.
The cells were allowed to recover in complete medium, synchronized in
G0 by growth factor deprivation, and plated at low density on microtiter
wells coated with 10 
 
m
 
g/ml poly-
 
L
 
-lysine or 20 
 
m
 
g/ml fibronectin in defined
medium (DME supplemented with 6.25 
 
m
 
g/ml insulin, 6.25 
 
m
 
g/ml transfer-
rin, 0.625 ng/ml selenous acid, 1.25 mg/ml BSA, and 5.35 
 
m
 
g/ml linoleic
acid) supplemented with 20 ng/ml PDGF and 10 
 
m
 
M BrdU. After 16 h, the
cells were fixed and stained with X-gal followed by anti-BrdU mAb and
AP-conjugated anti-mouse IgGs. The percentage of X-gal positive cells
that had incorporated BrdU was evaluated microscopically after light
counterstaining with hematoxylin.
 
Results
 
Integrins Activate JNK and
TRE-dependent Transcription
 
Preliminary experiments were conducted to examine if
JNK was physiologically activated in primary cells pro-
gressing through the G1 phase of the cell cycle. HUVECs
were synchronized in G0 by growth factor deprivation and
detached to simulate the cell rounding physiologically oc-
curring at mitosis. They were then plated on fibronectin in
the presence of growth factors to allow entry into and pro-
gression through G1.
In vitro kinase assays with the NH
 
2
 
-terminal fragment of
c-Jun as a substrate showed that JNK is activated to a sig-
nificant level during mid-G1, before the activation of the
D-type cyclin-dependent kinase CDK4 (Fig. 1). Peak JNK
activity was observed 4 h after entry into G1. In contrast,
the activation of ERK was biphasic with a first peak 10 to
20 min after entry into G1 and a second minor peak 8 h
later (Fig. 1). Since unstimulated cells are known to con-
tain detectable levels of c-Jun, but not c-Fos (Karin, 1995),
the rapid activation of ERK at the onset of G1 may serve
to induce serum response element (SRE)-dependent tran-
scription of the c-Fos gene before JNK-mediated tran-
scriptional activation of c-Jun. The AP-1 transcription fac-
tor Fos/Jun may then promote the expression of genes
necessary for G1 progression. The extent and timing of
JNK activation during the cell cycle are thus consistent
with a potential role in the control of G1 progression.
We next compared the ability of integrins and growth
factor receptors to activate JNK in NIH-3T3 fibroblasts.
Preliminary experiments showed that the activity of JNK
was significantly higher in growth factor deprived, stably
adherent cells than in cells that had been detached and im-
mediately lysed (Fig. 2 A). In accordance with the previ-
ous observation that several growth factors cause a rela-
tively modest activation of JNK (Kyriakis et al., 1994;
Minden et al., 1994), exposure to mitogenic concentrations
of PDGF, bFGF, and insulin increased the activity of JNK
only to a limited extent in growth factor starved, stably ad-
herent NIH-3T3 cells. In contrast, PDGF, bFGF, and to a
minor extent, insulin, caused a significant activation of
ERK under the same conditions (Fig. 2 A).
To further examine the relative contribution of integrins
and growth factor receptors to the activation of JNK,
NIH-3T3 cells were either plated on fibronectin in the ab-
sence of growth factors or treated with various doses of
PDGF while in suspension. As shown in Fig. 2 B, adhesion
to fibronectin induced a rapid, strong, and protracted acti-
vation of JNK. By contrast, JNK activity increased only
slowly and modestly over time in suspension, perhaps in
response to the activation of a stress pathway, as observed
by others (Frisch et al., 1996a; Khwaja and Downward,
1997). The activation of JNK caused by integrin ligation
was comparable in intensity to that observed in cells
treated with 5 to 10 ng/ml TNF-
 
a
 
 (Fig. 2 B), a known acti-
Figure 1. Activation of JNK and ERK during the G1 phase of
the cell cycle in primary cells. HUVECs were synchronized in
G0, detached, and then were lysed (G0) or replated on fibronec-
tin for the indicated times in SFM supplemented with growth fac-
tors and then lysed. JNK was precipitated from extracts contain-
ing equal amounts of total proteins by using GST-Jun beads and
subjected to an in vitro kinase assay. The position of phosphory-
lated GST-Jun is indicated. Total lysates containing the same
amount of proteins were subjected to immunoblotting with an-
tiphospho-ERK (ERK-P). The blot was stripped and reprobed
with antibodies to ERK 1 to demonstrate equal loading (ERK).
Peak activation of Cyclin D/CDK 4 and Cyclin E/CDK 2 occurs
at the indicated times in HUVECs under these experimental con-
ditions (F.G. Giancotti, unpublished results). 
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This effect of PDGF may be related to its ability, when
used at mitogenic concentrations as were used here, to
transiently disrupt the cytoskeleton and thus delay inte-
grin-mediated activation of FAK (Rankin and Rozengurt,
1994). Taken together, these observations indicate that
JNK is activated by integrins, but only to a limited extent
by PDGF, bFGF, and insulin. Exposure to growth factors
may, however, contribute to sustain the activation of JNK
caused by integrin ligation.
Phosphorylation of c-Jun by JNK is required for tran-
scriptional activation of the dimeric transcription factor
AP-1 and for the oncogenic cooperation between c-Jun
and Ha-Ras (Smeal et al., 1991). To examine if the activa-
tion of JNK caused by integrin ligation could contribute to
immediate early gene expression by promoting AP-1 de-
pendent transcription from TRE, NIH-3T3 cells were
transiently transfected with a vector encoding the lu-
ciferase gene under the transcriptional control of a TRE
and plated on fibronectin in the presence or absence of
PDGF. As shown in Fig. 2, D and E, adhesion to fibronec-
tin promoted TRE-dependent transcription with kinetics
that closely followed that of JNK activation. Simultaneous
exposure to PDGF caused a delay in the transcriptional
response to fibronectin, as observed for the activation of
JNK. The induction of TRE-dependent transcription by
integrins required the transcriptional activity of c-Jun be-
cause it was suppressed by the TAM-67 dominant-nega-
tive form of the transcription factor (93.3% inhibition). In-
tegrin-mediated activation of ERK and SRE-dependent
transcription of Fos (Wary et al., 1996; Mainiero et al.,
1997) can increase the levels of AP-1 available for phos-
phorylation by JNK. However, TRE-dependent transcrip-
tion could not have occurred in the absence of JNK-medi-
ated phosphorylation of c-Jun.
 
Integrin-mediated Activation of JNK Requires FAK, 
Src, p130
 
CAS
 
, Crk, and MKK
 
The mechanism by which integrins activate JNK was ex-
amined by introducing dominant-negative versions of vari-
ous signaling components into human embryonic kidney
293 cells. Since preliminary experiments suggested that the
ability to activate JNK is shared by all integrins, irrespec-
tive of whether they are able or not to recruit Shc (data
not shown), we decided to examine the role of FAK in this
process. Inactivating mutations were introduced at either
the Src SH2-binding site or the ATP-binding site of CD2-
FAK, a chimeric, membrane-anchored form of FAK that
localizes efficiently to focal adhesions (Chan et al., 1994;
Frisch et al., 1996b). We reasoned that membrane attach-
ment would promote the interaction of these FAK mu-
tants with focal adhesion components and thereby facili-
tate a dominant-negative effect.
As shown in Fig. 3, both CD2-FAK mutants exerted a
dominant-negative effect on fibronectin-mediated activa-
tion of JNK, indicating that this process requires the ki-
nase activity of FAK and its association with an Src family
kinase. Accordingly, integrin-mediated activation of JNK
was also suppressed by a kinase dead version of Src. In ad-
dition, we observed that the activation of JNK by integrins
is partially defective in Src
 
2
 
/
 
2
 
 and in Fyn
 
2
 
/
 
2
 
 fibroblasts, in
accordance with the notion that FAK can combine with
both kinases (data not shown). Integrin-mediated activa-
Figure 2. Adhesion to fi-
bronectin induces activation
of JNK and TRE-dependent
transcription. (A) After se-
rum starvation, NIH-3T3
cells were treated while ad-
herent with 20 ng/ml of
PDGF, 20 ng/ml bFGF, or
6.25  mg/ml insulin for 10 min,
or left untreated and either
detached (S) or adherent
(Starved). JNK was precipi-
tated from extracts contain-
ing equal amounts of total
proteins and subjected to an
in vitro kinase assay (GST-
Jun). Total lysates containing
the same amount of proteins
were subjected to immuno-
blotting with antiphospho-
ERK (Phospho-ERK). (B)
Serum starved NIH-3T3 cells
were detached and either left
in suspension (S) or plated
on fibronectin (Fn) in SFM
for the indicated times. Al-
ternatively, they were left ad-
herent and treated with the
indicated concentrations of
TNF-a for 15 min. JNK was
precipitated from extracts
containing equal amounts of
total proteins and subjected
to an in vitro kinase assay.
(C) Suspended cells were
treated with the indicated
concentrations of PDGF for
5 min and subjected to JNK
assay as above. (D) Sus-
pended cells were lysed (S)
or plated on fibronectin for
the indicated times in SFM
supplemented with or without 20 ng/ml PDGF during the last 5
min of adhesion (Fn1PDGF) before extraction. JNK assay was
performed as above. (E) NIH-3T3 cells were transfected with
pcoll TRE-tk-Luc. After serum starvation, the cells were de-
tached and left in suspension (S) or plated on fibronectin (Fn) for
the indicated times in SFM supplemented with or without 20 ng/
ml PDGF. Cell lysates containing equal amounts of total proteins
were subjected to luciferase assay. Values are expressed in arbi-
trary units. After cycloheximide-induced blockage of protein syn-
thesis, luciferase activity decays with a half-life of ,1 h in serum
starved NIH-3T3 cells replated on fibronectin (data not shown).
 
vator of JNK (Kyriakis et al., 1994; Minden et al., 1994).
Exposure to a wide range of PDGF concentrations caused
little or no activation of JNK in suspended cells (Fig. 2
C). Whereas exposure to 1 
 
m
 
g/ml lysophosphatidic acid
(LPA), which is known to activate FAK (Chrzanowska-
Wodnicka and Burridge, 1994), amplified the activation of
JNK caused by integrin ligation by 
 
z
 
70% (data not
shown), treatment with PDGF did not exert this effect.
However, PDGF changed the time course of JNK activa-
tion in cells adhering to fibronectin. Specifically, while ad-
hesion to fibronectin caused maximal stimulation of JNK
in 
 
z
 
10 min, simultaneous exposure to PDGF significantly
delayed the peak of activation of the kinase (Fig. 2 D). 
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tion of JNK was also blocked by a kinase inactive version
of MKK4, one of the major enzymes that binds to and
phosphorylates JNK (Fig. 4). In contrast, it was not inhib-
ited by expression of dominant-negative Ras (Fig. 3) or by
exposure to the PI-3K inhibitors Wortmannin (100 nM)
and LY294002 (50 
 
m
 
M) (data not shown). These results in-
dicate that the FAK/Src complex links integrins to MKK4
or a related enzyme, and thereby JNK. In addition, they
suggest that Ras and its substrate, PI-3K, which can acti-
vate Rac and thus JNK (Rodriguez-Viciana et al., 1994;
Nobes et al., 1995; Klippel et al., 1996), do not contribute
to this process.
To examine the mechanism by which the FAK/Src com-
plex activates JNK, we focused on the role of the docking/
adaptor proteins p130
 
CAS
 
 and paxillin, which bind to the
FAK/Src complex and become heavily phosphorylated on
tyrosine residues upon integrin engagement (Schaller and
Parson, 1995; Richardson and Parsons, 1996; Vuori et al.,
1996; Schlaepfer et al., 1997). The activation of JNK by in-
tegrins was inhibited to a significant extent by a mutant
form of p130
 
CAS
 
 carrying a deletion of the entire substrate
region (SD-CAS; Fig. 4). In contrast, a mutant form of
paxillin carrying phenylalanine substitutions at three ty-
rosine phosphorylation sites, including all the Crk binding
sites, inhibited this event modestly and only when ex-
pressed at relatively high levels (data not shown). These
results indicate that p130
 
CAS
 
 plays a major role, and paxil-
lin perhaps a minor one, in integrin-mediated JNK activa-
tion.
9 out of 15 tyrosine phosphorylation sites within the sub-
strate region of p130
 
CAS
 
 conform to the consensus motif
for binding to the SH2 domain of Crk (Sakai et al., 1994).
In addition to the SH2 domain, Crk contains either one or
two SH3 domains able to interact with downstream target-
effectors (Mayer et al., 1988; Matsuda et al., 1992; ten
Hoeve et al., 1993). Previous studies have indicated that
the adaptor function of Crk is regulated positively by re-
cruitment to the plasma membrane and negatively when
tyrosine 222 becomes phosphorylated and associates in-
tramolecularly with the SH2 domain (Mayer and Hana-
fusa, 1990; Feller et al., 1994).
We reasoned that an SH3 mutant form of the viral ver-
sion of Crk, which is anchored to the membrane via its gag
sequences and truncated before tyrosine 222, would have
interacted efficiently, via its intact SH2 domain, with
p130
 
CAS
 
, but not with downstream target effectors. As
shown in Fig. 4, expression of this mutant form of Crk
effectively suppressed JNK activation in cells plated on
fibronectin. Conversely, the introduction of a control
construct with a mutated SH2 domain stimulated the acti-
vation of JNK, suggesting that the recruitment of Crk to
the plasma membrane and its interaction with downstream
target(s) via the SH3 domain are sufficient to activate JNK
(Fig. 4). These observations indicate that the FAK/Src/
p130
 
CAS
 
 complex activates JNK by recruiting Crk to the
plasma membrane. They are also in agreement with pre-
vious studies implicating Crk in the activation of JNK
(Tanaka et al., 1997).
 
Integrin-mediated JNK Signaling Controls Cell
Cycle Progression
 
To examine whether FAK signaling to JNK was required
for cell proliferation, NIH-3T3 fibroblasts were transiently
transfected with various amounts of vectors encoding
wild-type and mutant versions of the signaling compo-
nents of this pathway, in combination with the marker
Figure 3. Role of the FAK/Src complex in integrin-mediated ac-
tivation of JNK. 293 cells were transiently transfected with 3 mg
of vector encoding FLAG-tagged JNK alone or in combination
with 3, 9, and 27 mg of plasmids encoding CD2-FAK K454R (cat-
alytically inactive), CD2-FAK Y397F (unable to bind to the SH2
domain of Src family kinases), and K2 Src (kinase dead), or with
9 and 27 mg of vector encoding DnRas (N17, dominant-negative).
The cells were serum starved for 24 h, detached, and lysed imme-
diately (S) or plated on fibronectin for 20 min (Fn). FLAG-
tagged JNK was immunoprecipitated from extracts containing
equal amounts of total proteins and subjected to an in vitro ki-
nase assay with GST-Jun as a substrate (A). Total lysates con-
taining the same amount of proteins were subjected to immuno-
blotting with antibodies to CD2, Src, and Ras to verify that the
expression of the various dominant-negative proteins was pro-
portional to the amount of DNA transfected (B). Immunoblot-
ting with anti-FLAG antibodies was used to verify equal expres-
sion of FLAG-JNK in all samples (C).
Figure 4. Role of p130CAS and Crk in integrin-mediated activa-
tion of JNK. 293 cells were transiently transfected with 3 mg of
vector encoding FLAG-tagged JNK alone or in combination with
3.75, 7.5, and 15 mg of plasmid encoding a mutant form of
p130CAS carrying a deletion of the entire substrate region (SD-
CAS), or with 3, 9, and 27 mg of plasmids encoding SH22 v-Crk
(SH2 mutant), SH32 v-Crk (SH3 mutant), and GST-DnMKK4
(kinase inactive). The cells were serum starved for 24 h, de-
tached, and solubilized immediately (S) or plated on fibronectin
for 20 min (Fn). FLAG-tagged JNK was immunoprecipitated
from extracts containing equal amounts of total proteins and sub-
jected to an in vitro kinase assay with GST-Jun as a substrate
(A). Total lysates containing the same amount of proteins were
subjected to immunoblotting with antibodies to p130CAS, gag, and
GST to verify that the expression of the various dominant-nega-
tive proteins was proportional to the amount of DNA transfected
(B). Immunoblotting with anti-FLAG antibodies was used to
verify equal expression of FLAG-JNK in all samples (C). 
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-galactosidase. The cells were synchronized in G0 and
plated on fibronectin in the presence of PDGF. Entry of
the transfected cells into S phase was evaluated by double
staining with X-gal and anti-BrdU antibodies.
While CD2-FAK, which is constitutively active (Chan
et al., 1994), promoted entry into the S phase to a limited
extent, its kinase dead version suppressed it (Fig. 5). In
both cases, the effects observed were dose dependent. In
addition, whereas wild-type p130
 
CAS
 
 did not affect pro-
gression through G1, a mutant version carrying a deletion
of the substrate region, which includes all the Crk binding
sites, partially inhibited transit through G1 (Fig. 5). The in-
complete effect of this mutant may be due to residual, in-
tegrin-induced binding of Crk to paxillin (Schaller and
Parsons, 1995). In accordance with this hypothesis, domi-
nant-negative Crk suppressed entry into S phase as effec-
tively as the kinase dead version of CD2-FAK. Finally, cell
cycle progression was also suppressed by dominant-nega-
tive versions of MKK4 and Jun (Fig. 5). These findings
suggest that integrin-mediated activation of the FAK–
JNK pathway is necessary for progression through the G1
phase of the cell cycle.
Discussion
Although the details of FAK’s interaction with a number
of cytoskeletal and signaling components are known, the
biological function of this kinase is incompletely under-
stood. Our results suggest that FAK mediates activation of
JNK and c-Jun in response to integrin ligation, and by do-
ing so, regulates progression through the G1 phase of the
cell cycle.
What is the mechanism by which FAK activates JNK?
Upon activation, FAK undergoes autophosphorylation at
tyrosine 397 and combines with the SH2 domain of Src or
Fyn (Parsons, 1996). The most prominent substrates of
the FAK/Src complex are the docking adaptor proteins
p130CAS and paxillin (Schaller and Parsons, 1995; Richard-
son and Parsons, 1996; Vuori et al., 1996). Both contain ty-
rosine phosphorylation sites conforming to the consensus
for binding to the adaptor protein Crk. However, while
paxillin has only two such sites and does not appear to as-
sociate efficiently with Crk in response to integrin ligation
(Schaller and Parsons, 1995), p130CAS contains nine Crk-
binding motifs and associates well with Crk in cells adher-
ing to fibronectin (Vuori et al., 1996). Our results indicate
that the expression of dominant-negative versions of FAK,
Src, p130CAS, and Crk suppress the activation of JNK by
integrins. Together with complementary results of a recent
study (Dolfi et al., 1998), these findings provide evidence
that integrin-mediated activation of JNK requires the as-
sociation of FAK with Src (or Fyn) and p130CAS, and the
recruitment of Crk. It is unlikely that the coupling of Ras
to Rac mediated by PI-3K (Rodriguez-Viciana et al., 1994;
Nobes et al., 1995; Klippel et al., 1996) contributes in a sig-
nificant manner to the activation of JNK by integrins be-
cause a dominant-negative form of Ras and specific inhibi-
tors of PI-3K did not interfere with activation of this
pathway. Thus, it appears that the b1 and av integrins acti-
vate JNK and ERK via two separate pathways (see Fig. 6
for a model). By contrast, the a6b4 integrin, which is pre-
sumably unable to activate FAK because it does not con-
tain the sequences required for its recruitment, is coupled
to JNK signaling via the Ras–PI-3K–Rac pathway (Maini-
ero et al., 1997).
The mechanism by which Crk activates JNK in response
to integrin ligation remains to be examined. Crk is known
to interact via one of its SH3 domains with the exchange
factor C3G (Tanaka et al., 1994) and previous studies have
indicated that C3G is required for activation of JNK by
the viral oncoprotein v-Crk (Tanaka et al., 1997). Interest-
ingly, the activation of JNK by v-Crk and C3G appears to
require the sequential action of the mixed lineage kinases
MLK3 and DLK, but not the activity of Rho family GTP-
ases or PAK proteins (Tanaka and Hanafusa, 1998). In ad-
dition, or instead, Crk may activate Rac, and thereby JNK,
by promoting the association of C3G with DOCK 180 or
mSOS (Dolfi et al., 1998).
The identity of genes regulated by JNK is largely un-
known, but they must include genes important for cell pro-
liferation. The evidence for this is several fold: first, dereg-
ulated expression of c-Jun or its mutated viral version v-Jun
is sufficient to cause neoplastic transformation of primary
avian and mammalian fibroblasts (Vogt, 1994); second,
primary fibroblasts derived from c-Jun2/2 mice display a
severe proliferation defect (Johnson et al., 1993); and
third, several oncoproteins, including v-Src, activated Ras,
v-Crk, Bcr-Abl, and Met, potently activate JNK and there
is evidence to suggest that this activation is required to
Figure 5. Integrin-mediated activation of JNK is required for
progression through the G1 phase of the cell cycle. NIH-3T3 fi-
broblasts were transiently transfected with 1 mg of vector encod-
ing b-galactosidase alone or in combination with the indicated
amounts of plasmids encoding CD2-FAK, CD2-FAK K454R,
GST-CAS (wild-type), GST-SD-CAS (substrate region deleted),
v-Crk, SH32 v-Crk, GST-Wt MKK4 (wild-type), GST-Dn
MKK4, Dn-Jun (D3-122), or Dn-RAS (N17). After synchroniza-
tion in G0 by serum deprivation, the cells transfected only with
the b-galactosidase plasmid were plated on coverslips coated
with poly-L-lysine (PL, white bar) or fibronectin (Fn, black bar),
while those cotransfected with vectors encoding wild-type and
constitutively active proteins (stippled bars) or corresponding
dominant-negative versions (gray bars) were plated only on fi-
bronectin. After 16 h of incubation in defined medium supple-
mented with PDGF and BrdU, the cells were fixed and stained
with anti-BrdU mAb. The number of transfected cells entering S
phase was evaluated as described in Materials and Methods. Un-
der these conditions, none of the cells plated on fibronectin in the
absence of PDGF enter into S phase. The diagram shows the
mean value and standard deviation from triplicate samples.Oktay et al. Regulation of JNK and Cell Cycle Progression by FAK 1467
cause neoplastic transformation (Derijard et al., 1994;
Minden et al., 1995; Raitano et al., 1995; Johnson et al.,
1996; Rodrigues et al., 1997; Tanaka et al., 1997).
Despite the clear requirement for c-Jun transcriptional
activity in cell proliferation, it has been difficult to identify
a physiological, nonstress stimulus for JNK consistent with
its role in the regulation of AP-1 transcription. With the
notable exception of EGF, mitogenic neuropeptides, and
muscarinic receptor ligands, which indeed activate FAK or
the related kinase PYK-2 (Zachary et al., 1992; Coso et al.,
1995; Tokiwa et al., 1996; Yu et al., 1996; Cadwallader et al.,
1997; Higashita et al., 1997; Logan et al., 1997; Slack,
1998), most growth factors cause a relatively modest acti-
vation of JNK (Kyriakis et al., 1994; Minden et al., 1994).
Our results indicating that integrin ligation causes a signif-
icant activation of JNK and TRE-dependent transcription
provide a physiological stimulus for JNK signaling that is
consistent with its role in the control of cell proliferation.
Our present results imply that FAK, which appears to
be activated by all b1 and av integrins, is required during
G1 progression because of its ability to activate JNK. Re-
cently, it has been shown that a mutant form of FAK,
which is truncated at the COOH terminus and thus unable
to localize to focal adhesions, interferes with both fi-
bronectin-induced activation of ERK and progression
through the cell cycle (Zhao et al., 1998). On the basis of
these results, it has been argued that FAK regulates cell
proliferation by stimulating ERK. However, an alternative
explanation is that this truncated form of FAK acts as a
cytoplasmic sink for all Src-family kinases and thus dis-
rupts not only FAK, but also Shc signaling. In accordance
with this hypothesis, two more specific dominant-negative
forms of FAK, FRNK and FAK-Y397F, inhibit ERK acti-
vation to a much lesser degree, but interfere with cell pro-
liferation nonetheless (Zhao et al., 1998; see also Gilmore
and Romer, 1996). Although additional mechanisms can-
not be excluded, our observation that dominant-negative
forms of FAK, p130CAS, Crk, MKK4, and Jun all inhibit
entry into the S phase provides evidence that FAK regu-
lates cell proliferation by activating JNK.
If FAK is required for cell cycle progression, why then
do the FAK2/2 cells not display an obvious proliferation
defect (Ilic et al., 1995)? There are two potential explana-
tions. First, it is now apparent that the FAK2/2 cells origi-
nally examined by Ilic and colleagues also lack a func-
tional form of the cell cycle regulator p53 (Furuta et al.,
1995). Some of the cell lines generated more recently do
have wild-type p53, but are transformed by the polyoma
middle T antigen (Ilic et al., 1998). It is possible that the
lack of p53 or presence of middle T antigen bypasses the
requirement for FAK during cell proliferation. In addi-
tion, it recently has been shown that FAK2/2 cells have el-
evated levels of PYK-2, which may compensate, at least in
part, for the lack of FAK (Sieg et al., 1998).
The mitogenic signaling pathway linking integrins to
JNK is likely to be deregulated in, and to contribute to, the
transformation of at least some neoplastic cells. Previous
studies have provided evidence that FAK is overexpressed
in invasive carcinomas (Owens et al., 1995) and that the
constitutively active CD2-FAK induces anchorage-inde-
pendent growth in MDCK cells (Frisch et al., 1996b). In
addition, the viral version of Src is a potent oncogene ca-
pable of transforming a variety of cells types, and there is
strong genetic evidence that p130CAS is a necessary sub-
strate of v-Src-induced transformation (Honda et al.,
1998). In accordance with these findings, we have ob-
served that CD2-FAK and p130CAS cooperate with acti-
vated Raf to induce anchorage-independent growth in
NIH-3T3 cells (F. Liu and F.G. Giancotti, unpublished re-
sults). Finally, v-Crk and v-Jun are potent oncogenes
(Mayer et al., 1988; Vogt, 1994). Taken together, these ob-
servations suggest that the FAK–JNK pathway can con-
tribute to neoplastic transformation.
Previous studies have provided evidence that a6b4 and
a subset of b1 and av integrins activate the Ras-ERK sig-
naling cascade by recruiting Shc (Mainiero et al., 1995;
1997; Wary et al., 1996; 1998). Mitogens and Shc-linked in-
tegrins synergize to promote transcription from the Fos
SRE. Accordingly, ligation of integrins linked to Shc en-
ables these cells to progress through the G1 phase of the
cell cycle in response to mitogens, whereas adhesion medi-
ated by other integrins results in growth arrest, despite the
presence of mitogens. These mechanisms also appear to
operate in vivo, as mice lacking the integrin a1 subunit or
the cytoplasmic domain of b4 display cell cycle defects
consistent with the lack of Shc signaling (Murgia et al.,
Figure 6. Model of anchorage-dependent cell growth. Shc-linked
integrins and growth factors receptors cooperate to activate the
Ras-ERK cascade and promote the transcription of c-Fos. All b1
and av integrins stimulate the FAK–JNK pathway in the absence
of a significant input from growth factor receptors and induce
transcription of c-Jun, as well as activation of newly formed Fos/
Jun dimers. The Journal of Cell Biology, Volume 145, 1999 1468
1998; Pozzi et al., 1998). These data suggest that integrin-
mediated Shc signaling is necessary for cell cycle progres-
sion.
The results of this and previous studies support the
model that integrins control cell cycle progression prima-
rily by regulating immediate early gene expression (Fig.
6). While Shc-linked integrins and growth factor receptors
cooperate to activate the Ras-ERK cascade and promote
SRE-dependent transcription of c-Fos, all b1 and av inte-
grins appear to be able to stimulate the FAK–JNK path-
way in the absence of a significant contribution from
growth factor receptors. It is likely that, in response to in-
tegrin ligation, JNK not only acts on preexisting Jun/ATF2
and ATF2/ATF2 dimers, thereby promoting the CRE-
dependent transcription of c-Jun, but also activates the
Fos/Jun dimers formed in response to the coordinated ac-
tion of both integrins and growth factor receptors. The ex-
istence of a signaling pathway activated by all integrins
within a signaling network coordinately regulated by a
subset of integrins and growth factor receptors ensures
that the control of cell proliferation exerted by the extra-
cellular matrix is both stringent and integrin-specific.
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